By dividing 79 glioma patients into high and low ADAMTS9-AS1 expression group, we further demonstrated that ADAMTS9-AS1 expression level was correlated with tumor size and the WHO grade, which served as an independent prognostic factor affecting the overall survival of glioma patients. This evidence concerns the gene ADAMTS9 and central nervous system cancer.